Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance - 04/12/18
On behalf the
FHU ACRONIM2
pages | 7 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Initial acceptance of switching from originator to biosimilar CT-P13 for non-medical reason was excellent (89%). |
• | Nearly half of the 28% patients who discontinued CT-P13 did not present objective disease activity. |
• | This poor secondary acceptance suggests that patient information, fears and beliefs influence switch outcome. |
Abstract |
Objective |
To explore acceptance and retention rate of biosimilar CT-P13 after switching from originator infliximab (OI) in patients with various rheumatic diseases.
Methods |
Patients with stable rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA) under OI were proposed to switch to CT-P13 at the same regimen. A prospective cohort of infliximab-naïve patients beginning CT-P13 and a retrospective cohort of patients treated with OI were used as controls. The primary outcome was to evaluate the retention rate of CT-P13. Secondary outcomes were the switch acceptance rate, reasons of failure and safety.
Results |
Switch was proposed to 100 patients and accepted by 89 of them (63 AS, 12 PsA and 14 RA). After a median follow-up of 33 weeks, 72% of patients were still treated with CT-P13. This retention rate was significantly lower than the one found in our retrospective and prospective control cohorts: 88% and 90% respectively (P-value=0.0002). Within patients who asked to be reswitched to OI, 13/25 (52%) presented clinical disease activity, one developed serum sickness and 11 (44%) presented no objective activity. A subanalysis excluding these 11 patients abrogated difference in retention rates between the 3 cohorts (P-value=0.453). After reswitching to OI, patients without objective disease activity claimed to recover original efficacy.
Conclusions |
Retention rate was lower after switching from OI to CT-P13 compared to our control cohorts. However, this difference faded after excluding patients without objective clinical activity, suggesting a reluctance of patients to the switch and a negative perception of the biosimilar.
Le texte complet de cet article est disponible en PDF.Keywords : Rheumatoid arthritis, Ankylosing spondylitis, Spondyloarthropathies, Patient attitude to health, Anti-TNF-alpha, DMARDs (biologics)
Plan
Vol 85 - N° 5
P. 561-567 - octobre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?